Why the study?
Does phenylbutazone improve superficial thrombophlebitis in patients with refractory disease?
Observational (n=132)
Does phenylbutazone improve superficial thrombophlebitis in patients with refractory disease?
A short course of phenylbutazone appears effective and relatively safe for resolving refractory superficial thrombophlebitis.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for refractory superficial thrombophlebitis; hypothesis-generating case series requires randomized confirmation.
Phenylbutazone is a potent anti-inflammatory agent. It was effective in modifying or causing the resolution of superficial thrombophlebitis in the extremities of 132 patients in whom this condition had proven refractory or difficult to manage. The short course of treatment which proved necessary to accomplish this end, makes this drug a practical and relatively safe addition to the management of superficial vein inflammation.
No takes yet. Share an insight, caveat, or question.
Irwin D. Stein (1955) conducted an observational in Superficial thrombophlebitis (n=132). Phenylbutazone (Butazolidin) was evaluated on Modifying or causing the resolution of superficial thrombophlebitis.
Synapse has enriched 10 related papers. Consider them for comparative context: